

Although *M. mageritense* has been isolated from cutaneous lesions of a tsunami survivor (7) and from 2 patients who received footbaths at the same nail salon (6), in most of these case reports, such as for our case, the source of contamination was unknown. Thus, *M. mageritense* is a rapidly growing mycobacteria that can cause granulomatous lymphadenitis in children. Clinicians should be aware of this bacteria during differential diagnoses.

Acknowledgment

We thank Jaime Esteban for providing assistance with antimicrobial drug susceptibility testing.

About the Author

Dr. García-Boyano is a doctoral candidate in pediatric infectious diseases at the Hospital Universitario La Paz, Madrid. His primary research interests are tropical medicine, HIV, and healthcare-associated infections.

References

1. Domenech P, Jimenez MS, Menendez MC, Bull TJ, Samper S, Manrique A, et al. *Mycobacterium mageritense* sp. nov. *Int J Syst Bacteriol*. 1997;47:535–40. <https://doi.org/10.1099/00207713-47-2-535>
2. Wallace RJ Jr, Brown-Elliott BA, Hall L, Roberts G, Wilson RW, Mann LB, et al. Clinical and laboratory features of *Mycobacterium mageritense*. *J Clin Microbiol*. 2002;40:2930–5. <https://doi.org/10.1128/JCM.40.8.2930-2935.2002>
3. Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of *Mycobacteria*, *Nocardia* spp, and other aerobic Actinomycetes. CLSI supplement M62. Wayne (PA): The Institute; 2018.
4. Okabe T, Sasahara T, Suzuki J, Onishi T, Komura M, Hagiwara S, et al. *Mycobacterium mageritense* parotitis in an immunocompetent adult. *Indian J Microbiol*. 2018;58:28–32. <https://doi.org/10.1007/s12088-017-0692-y>
5. Kim J, Seong MW, Kim EC, Han SK, Yim JJ. Frequency and clinical implications of the isolation of rare nontuberculous mycobacteria. *BMC Infect Dis*. 2015;15:9. <https://doi.org/10.1186/s12879-014-0741-7>
6. Gira AK, Reisenauer AH, Hammock L, Nadiminti U, Macy JT, Reeves A, et al. Furunculosis due to *Mycobacterium mageritense* associated with footbaths at a nail salon. *J Clin Microbiol*. 2004;42:1813–7. <https://doi.org/10.1128/JCM.42.4.1813-1817.2004>
7. Appelgren P, Farnébo F, Dotevall L, Studahl M, Jönsson B, Petrini B. Late-onset posttraumatic skin and soft-tissue infections caused by rapid-growing mycobacteria in tsunami survivors. *Clin Infect Dis*. 2008;47:e11–6. <https://doi.org/10.1086/589300>

Address for correspondence: Miguel García-Boyano, C/ Ginzo de Limia 55, 9°C, Madrid 28034, Spain; email: miguelgarciaoyano@gmail.com

SARS-CoV-2 Breakthrough Infections after Introduction of 4 COVID-19 Vaccines, South Korea, 2021

Seonju Yi,¹ Young June Choe,¹ Jia Kim, Yoo-Yeon Kim, Ryu Kyung Kim, Eun Jung Jang, Do Sang Lim, Hye Ryeon Byeon, Sangwon Lee, Eonjoo Park, Seung-Jin Kim, Young-Joon Park

Author affiliations: Korea Disease Control and Prevention Agency, Cheongju, South Korea (S. Yi, J. Kim, Y.-Y. Kim, R.K. Kim, E.J. Jang, D.S. Lim, H.R. Byeon, S. Lee, E. Park, S.-J. Kim, Y.-J. Park); Korea University Anam Hospital, Seoul, South Korea (Y.J. Choe)

DOI: <https://doi.org/10.3201/eid2803.212210>

We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).

Since their rollout, vaccines have been highly effective globally in controlling coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Breakthrough infections have been reported in some vaccine recipients, suggesting the need for public health assessment and monitoring (2). To date, the vaccine-specific data on breakthrough infections are limited. In early 2021, the national immunization program of South Korea introduced 4 COVID-19 vaccines: ChAdOx1 nCov-19 (AstraZeneca, <https://www.astrazeneca.com>), BNT162b2 (Pfizer-BioNTech, <https://www.pfizer.com>), Ad26.COV2.S (Johnson & Johnson/Janssen [hereafter Janssen], <https://www.janssen.com>), and mRNA-1273 (Moderna, <https://www.moderna.com>). As of October 10, 2021, a total of 70% of the country's population have received ≥ 1 dose of vaccine (3). Introduction of the vaccines provided an opportunity to study breakthrough infections by different vaccine types. We describe a snapshot of SARS-CoV-2 breakthrough infections in South Korea and aim to identify risk by age group that might influence the observed pattern.

We conducted a nationwide retrospective cohort study to estimate SARS-CoV-2 breakthrough

¹These authors contributed equally to this article.

infection rates among AstraZeneca, Pfizer-BioNTech, Janssen, and Moderna vaccine recipients in South Korea. We included fully vaccinated persons (2 weeks past 2-dose vaccination for AstraZeneca, Pfizer-BioNTech, and Moderna vaccines; 2 weeks past 1-dose vaccination for Janssen vaccine) without history of SARS-CoV-2 infection (Appendix Figure 1, <https://wwwnc.cdc.gov/EID/article/28/3/21-2210-App1.pdf>). A Pfizer-BioNTech booster vaccination was offered to AstraZeneca vaccine-primed persons (2 doses of AstraZeneca vaccine, then a third dose of Pfizer-BioNTech vaccine), who were thereafter included in the analysis. Observed periods were April 7–October 10, 2021, for AstraZeneca vaccine; April 3–October 10, 2021, for Pfizer-BioNTech vaccine; June 24–October 10, 2021, for Janssen vaccine; July 30–October 10, 2021, for Moderna vaccine; and July 19–October 10, 2021, for AstraZeneca/Pfizer-BioNTech prime/booster recipients.

We estimated breakthrough infection rate by vaccine, number of serious outcomes (cases treated with high-flow oxygen therapy, mechanical ventilator, extracorporeal membrane oxygenation, continuous renal replacement therapy, or death), and number of secondary transmissions originated from the breakthrough infection case. We identified the presence of serious outcomes through the case reporting form collected under the Infectious Disease Control and Prevention Act, which mandates epidemiologic investigation on all confirmed SARS-CoV-2 cases in South Korea. In all close contacts of laboratory-confirmed SARS-CoV-2 case-patients, we conducted epidemiologic investigations to search for the preceding link and potential onward transmission cases. We calculated age-adjusted and age-specific breakthrough infection rates as well as age-adjusted rates for serious outcomes and deaths. We randomly tested ≈20% of samples for full-length genome and spike protein sequencing to identify the presence of variant of concern.

The number of vaccinations by vaccine type are as follows: AstraZeneca (prime/booster), 8,737,343 persons; Pfizer-BioNTech (prime/booster), 10,235,891 persons; Janssen (single), 1,408,921 persons; Moderna

(prime/booster), 1,190,973 persons; and AstraZeneca/Pfizer-BioNTech (prime/booster), 1,600,998 persons (Table). Age-adjusted breakthrough infection rate per month was highest among Ad26.COV2.S recipients (42.6/100,000 population), followed by AstraZeneca (prime/booster) recipients (21.7/100,000 population), AstraZeneca/Pfizer-BioNTech (prime/booster) recipients (21.3/100,000 population), Pfizer-BioNTech (prime/booster) recipients (8.5/100,000 population), and Moderna (prime/booster) recipients (1.8/100,000 population). Serious outcome (0–0.9/100,000 population) and death (0–0.2/100,000 population) after breakthrough infection were rare for all vaccine types. Secondary transmission rate was highest among Janssen recipients (19.2/100,000 population), followed by AstraZeneca (prime/booster) recipients (4.9/100,000 population).

The highest breakthrough infection rates we observed in younger age groups were in AstraZeneca (prime/booster), Janssen (single), Moderna (prime/booster), and AstraZeneca/Pfizer-BioNTech (prime/booster) recipients (Figure). Among the Pfizer-BioNTech (prime/booster) recipients, breakthrough infection rate was highest among elderly persons 70–79 years and ≥80 years of age (Appendix Figure 2).

We identified the variants of concern found in AstraZeneca (prime/booster) recipients as 1,285 Delta and 4 Alpha variants; in Pfizer-BioNTech (prime/booster) as 888 Delta, 14 Alpha, and 1 Beta variants; in Janssen (single), 789 Delta, 12 Alpha, and 2 Gamma variants; in Moderna (prime/booster), 13 Delta variants; and in AstraZeneca/Pfizer-BioNTech (prime/booster), 188 Delta variants.

Our findings of a higher breakthrough infection in adenovirus DNA vector vaccine recipients and lower risk among mRNA vaccine recipients are consistent with other studies. In clinical trials, 0.5% of AstraZeneca recipients (4) and 0.3% of Janssen recipients (5) had SARS-CoV-2 infections, whereas 0.05% of Pfizer-BioNTech recipients (6) and 0.08% of Moderna recipients (7) had infections. The AstraZeneca/Pfizer-BioNTech (prime/booster) recipients had breakthrough infection rate in between that of

Table. Severe acute respiratory syndrome coronavirus 2 breakthrough infections by vaccine type, South Korea, 2021

Variable	ChAdOx1 nCov-19, AstraZeneca, prime/booster	BNT162b2, Pfizer-BioNTech, prime/booster	Ad26.COV2.S, Johnson & Johnson/Janssen, single dose	mRNA-1273, Moderna, prime/booster	ChAdOx1 nCov-19/BNT162b2, AstraZeneca/Pfizer-BioNTech, prime/booster
Observed period	Apr 7–Oct 10	Apr 3–Oct 10	Jun 24–Oct 1	Jul 30–Oct 10	Jul 19–Oct 10
Total vaccinations, no.	8,737,343	10,235,891	1,408,921	1,190,973	1,600,998
Breakthrough infections*	21.7	8.5	42.6	1.8	21.3
Serious outcomes*	0.3	0.2	0.9	0.0	0.1
Deaths*	0.2	0.0	0.0	0.0	0.1
Secondary transmission*	4.9	2.1	19.2	0.4	2.0

*Monthly age-adjusted rate per 100,000 population.

AstraZeneca (prime/booster) and Pfizer-BioNTech (prime/booster) recipients, suggesting a potential benefit from mix-and-match vaccination as observed in previous studies (8).




Figure. Age-specific breakthrough infection rates (cases/100,000 population) of severe acute respiratory syndrome coronavirus 2 for 4 vaccines by vaccine type, South Korea. A) ChAdOx1 nCov-19 (AstraZeneca prime/booster), April–October 2021. B) BNT162b2 (Pfizer-BioNTech prime/booster), April–October 2021. C) Ad26.COV2.S (Johnson & Johnson/Janssen, single dose), June–October 2021. D) mRNA-1273 (Moderna, prime/booster), July–October 2021. E) ChAdOx1 nCov-19/BNT162b2 (AstraZeneca prime/Pfizer-BioNTech booster), July–October 2021

A limitation of this study is that the observed period between the vaccines were different: AstraZeneca and Pfizer-BioNTech were available for nearly 6 months, whereas Janssen and Moderna were introduced 2–3 months later. We conducted monthly adjustments of daily data; however, unidentified confounders may have affected the observed result. In addition, emergence of new variants may also affect the risk for breakthrough infection (9). Since mid-June 2021, Delta variant has become the dominant strain in South Korea, which may have affected vaccine effectiveness and postinfection health outcomes. Despite these limitations, our findings demonstrate uniformly low numbers of serious disease cases in recipients of all 4 vaccine types, consistent with previous findings (10).

In conclusion, breakthrough infection was more common among adenovirus DNA vector vaccine recipients than among mRNA vaccine recipients. Booster vaccination with mRNA vaccines in adenovirus DNA vector vaccine-primed individuals may confer additional protection against SARS-CoV-2 breakthrough infections.

Acknowledgments

We thank the relevant ministries, including the Ministry of Interior and Safety, Si/Do and Si/Gun/Gu, medical staffs in health centers, and medical facilities for their efforts in responding to COVID-19 outbreak.

About the Author

Dr. Yi is a public health officer at Korea Disease Control and Prevention Agency. Her main research interest is in epidemiologic investigation and surveillance measures of infectious diseases. Dr. Choe is a clinical assistant professor of pediatrics at Korea University Anam Hospital. His main research addresses quantification of and understanding the mechanisms of immunization program's impact on public health.

References

- Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. *N Engl J Med.* 2021;385:1355–71. 10.1056/NEJMoa2110362 <https://doi.org/10.1056/NEJMoa2110362>
- Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status – 13 U.S. Jurisdictions, April 4–July 17, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70:1284–90. 10.15585/mmwr.mm7037e1 <https://doi.org/10.15585/mmwr.mm7037e1>
- Korea Disease Control and Prevention Agency. COVID-19 vaccination dashboard [cited 2021 Oct 25]. <https://ncv.kdca.go.kr/eng/>

4. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397:99–111. 10.1016/S0140-6736(20)32661-1 [https://doi.org/10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1)
5. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. 2021;384:2187–201. 10.1056/NEJMoa2101544 <https://doi.org/10.1056/NEJMoa2101544>
6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383:2603–15. 10.1056/NEJMoa2034577 <https://doi.org/10.1056/NEJMoa2034577>
7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384:403–16. 10.1056/NEJMoa2035389 <https://doi.org/10.1056/NEJMoa2035389>
8. Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis*. 2021;21:1212–3. 10.1016/S1473-3099(21)00420-5 [https://doi.org/10.1016/S1473-3099\(21\)00420-5](https://doi.org/10.1016/S1473-3099(21)00420-5)
9. Blanquart F, Abad C, Ambrose J, Bernard M, Cosentino G, Giannoli J-M, et al. Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. *Euro Surveill*. 2021;26. 10.2807/1560-7917.ES.2021.26.37.2100824 <https://doi.org/10.2807/1560-7917.ES.2021.26.37.2100824>
10. Butt AA, Yan P, Shaikh OS, Mayr FB. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. *EClinicalMedicine*. 2021;40:101117. 10.1016/j.eclinm.2021.101117 <https://doi.org/10.1016/j.eclinm.2021.101117>

Address for correspondence: Young-Joon Park, Director of Epidemiologic Investigation, Korea Disease Control and Prevention Agency, Cheongju, South Korea; email: pahmun@korea.kr

Serial Intervals and Household Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021

Jin Su Song,¹ Jihee Lee,¹ Miyoung Kim, Hyeong Seop Jeong, Moon Su Kim, Seong Gon Kim, Han Na Yoo, Ji Joo Lee, Hye Young Lee, Sang-Eun Lee, Eun Jin Kim, Jee Eun Rhee, Il Hwan Kim, Young-Joon Park

Author affiliations: Capital Regional Center for Disease Control and Prevention, Seoul, South Korea (J.S. Song, J. Lee, M. Kim); Incheon Metropolitan Government, Incheon, South Korea (H.S. Jeong, M.S. Kim, S.G. Kim, H.N. Yoo); Korea Disease Control and Prevention Agency, Cheongju, South Korea (J.J. Lee, H.Y. Lee, S.-E. Lee, E.J. Kim, J.E. Rhee, I.H. Kim, Y.-J. Park)

DOI: <https://doi.org/10.3201/eid2803.212607>

To clarify transmissibility of the severe acute respiratory syndrome coronavirus 2 Omicron variant, we determined serial intervals and secondary attack rates among household contacts in South Korea. Mean serial interval for 12 transmission pairs was 2.9 days, and secondary attack rate among 25 households was 50.0%, raising concern about a rapid surge in cases.


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern has been confirmed on all continents and has spread through communities around the world at unprecedented speed (1). Given uncertainties about current estimates of virus transmissibility, we analyzed real-life data on serial intervals for transmission pairs (time from infector symptom onset to infectee symptom onset) and secondary attack rate among household contacts, offering metrics essential for predicting epidemic size, forecasting healthcare demand, and devising effective public health interventions. Details of the epidemiologic situation with regard to importation and transmission of the Omicron variant in South Korea have been described elsewhere (2). We further traced a total of 76 case-patients with Omicron infection that originated from 2 persons with imported cases (75 confirmed cases and 1 suspected case) and their contacts, focusing on infector-infectee relationships and household transmission during November–December 2021.

Because of the possibility of their being exposed to other potential sources of infection at church on


¹These authors contributed equally to this article.

SARS-CoV-2 Breakthrough Infections after Introduction of 4 COVID-19 Vaccine Types, South Korea, 2021

Appendix



Appendix Figure 1. Timeline of selected study population for severe acute respiratory syndrome coronavirus 2 breakthrough infection, South Korea, 2021.



Appendix Figure 2. Daily average number of severe acute respiratory syndrome coronavirus 2 breakthrough infection cases per week, 2 weeks after full COVID-19 vaccination, South Korea, 2021.